Last reviewed · How we verify
Tafluprost/timolol fixed combination
Tafluprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor, while timolol is a non-selective beta-blocker that decreases aqueous humor production, together reducing intraocular pressure.
Tafluprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor, while timolol is a non-selective beta-blocker that decreases aqueous humor production, together reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Tafluprost/timolol fixed combination |
|---|---|
| Also known as | Taptiqom |
| Sponsor | Aristotle University Of Thessaloniki |
| Drug class | Prostaglandin analog / beta-blocker fixed combination |
| Target | FP receptor (tafluprost); beta-2 adrenergic receptor (timolol) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Tafluprost binds to prostaglandin F (FP) receptors on the ciliary muscle and trabecular meshwork, enhancing drainage of aqueous humor through the uveoscleral pathway. Timolol blocks beta-2 adrenergic receptors in the ciliary body, reducing aqueous humor secretion. The combination provides complementary mechanisms to lower intraocular pressure more effectively than either agent alone.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Conjunctival hyperemia
- Eye irritation/discomfort
- Increased iris pigmentation
- Eyelash growth
- Bradycardia (timolol component)
Key clinical trials
- A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
- From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy (NA)
- 24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration. (PHASE4)
- Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing (PHASE4)
- 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy (PHASE4)
- Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy (PHASE4)
- Tafluprost-Timolol Preservative-free Fixed Dose Combination (FDC) Superiority Study Against Monotherapies (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: